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Signal peptide peptidasePresenilin is the catalytic component of the γ-secretase complex, a membrane-embedded aspartyl protease that
plays a central role in biology and in the pathogenesis of Alzheimer’s disease. Upon assembly with its three pro-
tein cofactors (nicastrin, Aph-1 and Pen-2), presenilin undergoes autoproteolysis into two subunits, each of
which contributes one of the catalytic aspartates to the active site. A family of presenilin homologs, including sig-
nal peptide peptidase, possess proteolytic activity without the need for other protein factors, and these simpler
intramembane aspartyl proteases have given insight into the action of presenilinwithin theγ-secretase complex.
Cellular and molecular studies support a nine-transmembrane topology for presenilins and their homologs, and
small-molecule inhibitors and cysteine scanning with crosslinking have suggested certain presenilin residues
and regions that contribute to substrate recognition and handling. Identiﬁcation of partial complexes has also of-
fered clues to protein–protein interactions within the γ-secretase complex. Biophysical methods have allowed
3Dviews of theγ-secretase complex and presenilins.Most recently, the crystal structure of amicrobial presenilin
homolog has conﬁrmed a nine-transmembrane topology and intramembranous location and proximity of the
two conserved and essential aspartates. The crystal structure also provides a platform for the formulation of
speciﬁc hypotheses regarding substrate interaction and catalysis as well as the pathogenic mechanism of
Alzheimer-causing presenilinmutations. This article is part of a Special Issue entitled: Intramembrane Proteases.
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Among the more surprising ﬁndings in biochemistry has been the
discovery of proteases that carry out hydrolysis within the hydropho-
bic environment of the lipid bilayer. These intramembrane-cleaving
proteases (I-CLiPs) include the zinc-containing site 2 protease (S2P)
family, the rhomboid family of serine proteases, and the presenilin
2887M.S. Wolfe / Biochimica et Biophysica Acta 1828 (2013) 2886–2897family of aspartyl proteases. All three families have their active sites
embedded within the membrane and cleave within the transmem-
brane domains of their respective substrates. While at ﬁrst it may
seemstrange for hydrolysis to occurwithinmembranes, no biochemical
or biophysical rules need be violated. Indeed, othermembrane proteins
serve as channels for water and ions, creating microenvironments by
which polar and charged species can pass through themembranewith-
out directly encountering the hydrophobic tails of membrane lipids.
The ﬁrst crystal structures of i-CLiPs, of rhomboids [1–5] and an
S2P [6], provided insight into how water can access the membrane-
embedded active sites, revealing pores or cavities by which water can
reach the catalytic residues without contacting membrane lipids. At the
same time, these structures suggested means by which substrate trans-
membrane domains might enter the active site through a lateral gating
mechanism. Results from biochemical experiments guided the interpre-
tation of themechanistic meaning of the crystal structures, and the struc-
tural results in turn suggested hypotheses that could be tested by further
biochemical experiments (e.g., [7]). Thus, the interplay between bio-
chemistry and structural biology has proven quite powerful in the study
of rhomboid serine I-CLiPs and S2P metallo I-CLiPs.
Presenilin-type aspartyl I-CLiPs, on the other hand, had been resis-
tant to crystallographic analysis until most recently. A new structure
from an archaeal presenilin-like protease is consistent with much of
what has been learned of this class of membrane-embedded enzyme
frommolecular and biochemical experiments andwill no doubt provide
a platform from which to design further biochemical experiments to-
ward understanding the workings of these proteases. Below I review
the discovery of the presenilin family of I-CLiPs followed by molecular
and biochemical evidence for membrane topology, stoichiometry, and
interactions with subunits, substrates, and inhibitors. Finally, biochem-
ical and biophysical evidence for the three-dimensional structure of
presenilins and γ-secretase complexes, along with the mechanistic im-
plications of these ﬁndings, will be discussed.
2. Discovery of presenilin and γ-secretase subunits
A key step in the pathogenesis of Alzheimer's disease is proteolysis
resulting in the formation of the amyloid-β peptide (Aβ), the principle
protein component of the characteristic cerebral plaques of the disease
[8,9]. The N-terminus of Aβ is produced from the amyloid β-protein pre-
cursor (APP) ﬁrst by the action of β-secretase, a membrane-tetheredDD
lumen/ex
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NTF
Fig. 1.Membrane topology of presenilins and APP and sites of proteolysis. Presenilin has nin
assembly with other members of the γ-secretase complex, presenilin undergoes autoproteol
(NTF, copper) and C-terminal fragment (CTF, gold). Each presenilin subunit contributes an
ectodomain shedding by β-secretase, with retention of a C-terminal fragment in the membr
the Aβ peptide to the lumenal/extracellular space and an ε site to release the APP intracellenzyme that resembles pepsin and other water-soluble aspartyl prote-
ases [10–14]. This proteolysis leads to membrane shedding of the large
luminal/extracellular APP domain (Fig. 1). The 99-residue membrane-
bound remnant is then cleaved in the middle of its transmembrane
region by γ-secretase, releasing Aβ and again near the inner leaﬂet at
the ε site to release the APP intracellular domain (AICD) [15]. Rare dom-
inant mutations in the APP gene, found in and around the Aβ region,
cause familial early-onset Alzheimer's disease, and these mutations
alter the production of Aβ or its aggregation properties, important evi-
dence for the amyloid hypothesis of Alzheimer pathogenesis [8,9].
Most recently, an APP mutation near the β-secretase cleavage site
that leads to reduced Aβ production was found to be protective for
Alzheimer's disease [16]. Alzheimer-causing mutations also occur
in one of the subunits of γ-secretase (see below).
Several more or less contemporaneous observations provided criti-
cal clues for the identiﬁcation of γ-secretase. First, genes encoding the
multi-pass membrane proteins presenilin-1 and presenilin-2 were dis-
covered in a search to identify other genes associated with familial,
early-onset Alzheimer's disease [17–19]. The disease-causing missense
mutations were soon found to alter how γ-secretase cuts APP, leading
to increased proportions of the more aggregation-prone 42-residue
form of Aβ (Aβ42) over the 40-residue form (Aβ40) [20–23]. Second,
knockout of presenilin genes eliminated γ-secretase cleavage of APP
[24–26]. Third, the types of compounds that could inhibit γ-secretase
contained moieties typically found in aspartyl protease inhibitors
[27,28]. These ﬁndings led to the identiﬁcation of two conserved trans-
membrane aspartates in the multi-pass presenilin that are critical for
γ-secretase cleavage of APP (Fig. 1), suggesting that presenilins might
be the responsible aspartyl proteases [29–31].
Presenilin is cut into two pieces, an N-terminal fragment (NTF)
and a C-terminal fragment (CTF) [32,33], the formation of which is
regulated by limiting cellular factor(s) [34]. NTF and CTF remain
physically associated in a high-molecular weight complex and are
metabolically stable [32,33,35–37]. These and other results suggested
that the NTF-CTF heterodimer is the biologically active form [30]. In-
triguingly, the NTF and CTF each contribute one of the essential and
conserved aspartates, suggesting that the γ-secretase active site
might be at the interface between these two presenilin fragments.
In strong support of this hypothesis, transition-state analog inhibitors
of γ-secretase, compounds designed to interact with the active site of
the protease, were found to bind directly to presenilin NTF and CTFγ
β
tracellular
cytosol
ε
Aβ
AICD
CTF
APP
e transmembrane domains and two conserved aspartates, in TMD 6 and TMD 7. Upon
ysis within the large loop connecting TMD 6 and TMD 7 to form an N-terminal fragment
aspartate to the active site. APP is a type I integral membrane protein that undergoes
ane that is subsequently cleaved by γ-secretase in at least two sites: a γ site to release
ular domain (AICD) into the cytosol.
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part of a larger multi-protein complex which constitutes γ-secretase
(see below).
At the same time presenilins were discovered as susceptibility loci
for Alzheimer's disease, they were also shown to be required for
Notch signaling [40], a pathway essential for cell differentiation dur-
ing development and beyond [41]. After Notch is synthesized in the
ER, the receptor is cleaved in its extracellular domain during its pas-
sage through the secretory pathway, and the two pieces so generated
remain associated [42]. Upon interaction with a cognate ligand,
Notch becomes susceptible to a second extracellular proteolysis, by
a membrane-tethered metalloprotease, near the membrane [43,44].
The membrane-associated remnant is then cleaved within its trans-
membrane domain by a presenilin-dependent γ-secretase-like prote-
ase [45], releasing the Notch intracellular domain (NICD). NICD
translocates to the nucleus and activates transcription after associat-
ing with the nuclear partner CSL (CBP/RBPjk, Su(H), Lag-1) [46].
Knock-in of a Notch-1 transmembrane mutation that greatly reduces
presenilin-mediated proteolysis leads to a lethal phenotype in mice
similar that seen in Notch-1 knockout mice, indicating that efﬁcient
γ-secretase cleavage is essential for Notch signaling during develop-
ment [47].
Since the discovery that Notch is cleaved by γ-secretase, dozens of
other substrates have been identiﬁed, including Erb-B4, E- and
N-cadherins, CD44, the low density lipoprotein receptor, Nectin-1,
and the Notch ligands Delta and Jagged [48,49]. Knowledge of the cel-
lular functions of these proteolytic events vary, but in the case of
N-cadherin, the produced intracellular domain associates with the
transcriptional activator CBP (CREB binding protein) and promotes
its migration to the cytosol and degradation by the proteasome [50].
Also, neuregulin-1-triggered cleavage of ErbB4 inhibits astrocyte dif-
ferentiation by interacting with repressors of astrocyte gene expres-
sion [51]. While cellular function can be ascribed in some cases, the
ability of γ-secretase to cleave so many different substrates and its
apparently poor sequence speciﬁcity raises the question of whether
a major role of this enzyme is to serve as a general degrading protease
for membrane-bound protein remnants [52]. Indeed, γ-secretase ap-
pears to be unique among intramembrane proteases in its ability to
process so many different substrates. Substrate recognition may be
determined by the helical conformation of the substrate transmem-
brane domain rather than by sequence, with the some helical destabi-
lization required near the cleavage site [49], a concept that may apply
to other intramembrane proteases as well [53–56].
The highly conserved role ofγ-secretase inNotch signaling and its im-
portance in developmentmade possible genetic screens in Caenorhabditis
elegans that identiﬁed two Notch modiﬁers, a single-pass membrane
protein anterior pharynx-defective 2 (APH-2 or nicastrin) and a multi-
pass protein Aph-1 [57–59]. Nicastrin was independently isolated bio-
chemically as a presenilin-associated protein and found to be essential
forγ-secretase processing of bothAPP andNotch [60]. A saturation screen
in C. elegans for presenilinmodiﬁers identiﬁed nicastrin and Aph-1 and as
well as presenilin enhancer 2 (Pen-2) [58]. All four proteins (presenilin,
nicastrin, Aph-1, and Pen-2) associate with one another [61,62] and
with an immobilized γ-secretase inhibitor [62,63]. Moreover, their
coexpression increased γ-secretase activity in both Drosophila and
mammalian cells [61,62] and reconstituted activity in yeast [64]. Be-
cause yeast have no such protease activity and contain no apparent
orthologs of thesemetazoan proteins, these ﬁndings strongly suggested
that this quartet of proteins is necessary and sufﬁcient for γ-secretase
activity. This was subsequently conﬁrmed through puriﬁcation of the
protease complex to virtual homogeneity [65].
3. Discovery of SPP and other presenilin homologs
The concept of presenilin as the catalytic component for γ-secretase
was considerably strengthened when signal peptide peptidase (SPP)was found to be a similar intramembrane aspartyl protease. SPP clears
remnant signal peptides from the membrane after their production by
signal peptidase (Fig. 2). However, this process apparently also plays a
role in immune surveillance, in which signal peptides from the major
histocompatibility complex (MHC) type I are cleaved by SPP and the
peptide products presented onto the cell surface as an indication to
natural killer cells whether MHC synthesis is proceeding normally [66].
In addition, SPP is exploited by the hepatitis C virus for the maturation
of its core protein, suggesting that this protease may be a suitable target
for antiviral therapy [67]. See review by Jin Ye (“Roles of intramembrane
proteases in virus lnfection and immunity”) in this special issue for
further details.
SPP was identiﬁed by afﬁnity labeling with a peptidomimetic in-
hibitor, and the protein sequence displayed intriguing parallels with
presenilin [68]. SPP contains two conserved aspartates, each predict-
ed to lie in the middle of the sixth or seventh transmembrane domain
(Fig. 2), and the aspartate-containing sequences resemble those
found in presenilins. Interestingly, prior to the identiﬁcation of SPP, a
computational search for presenilin-like proteins netted an entire family
of so-called presenilin homologs (PSHs) [69]; however, it is not yet clear if
all of these proteins have catalytic activity. Two homologs, SPP-like prote-
ases, SPPL2a and SPPL2b, have been found to cleave tumor necrosis factor
α [70] and the dementia-associated Bri2 protein [71], although the bio-
logical roles of these proteolytic events are unknown. See review by
Voss et al. (“Mechanism, speciﬁcity and physiology of SPP and SPP-like
proteases”) for a more detailed discussion.
SPP appears to be less complicated than γ-secretase. Expression of
human SPP in yeast reconstituted the protease activity, suggesting that
the protein has activity on its ownanddoes not require othermammalian
protein cofactors [68]. This has been conﬁrmed by the expression of var-
ious SPP orthologs in E. coli and puriﬁcation of active enzyme to homoge-
neity [72]. Moreover, unlike presenilins, SPP is not processed into two
pieces. Thus, SPP and other presenilin-like proteases that function as
single polypeptide chains may be more tractable enzymes for shedding
light on γ-secretase structure and function. Indeed, this has turned out
to be the case (see below).4. Topology of presenilins and other γ-secretase components
The topology of PS1 had been a subject of some controversy and
confusion, with evidence for 6, 7 or 8 transmembrane domains
(TMDs). This issue ﬁnally appeared to be settled using insertion of
glycosylation sequences into possible loop regions and near the
C-terminus, showing that presenilin-1 contains nine TMDs [73,74],
with the N-terminus in the cytosol and the C-terminus exposed to
the luminal/extracellular space (Fig. 1). The ﬁnal three transmem-
brane segments had been the difﬁcult ones to conﬁrm, one reason
apparently being their interdependence. TMD7 is a relatively short
hydrophobic domain, with one of the conserved aspartates in themiddle.
Incorporation of this TMD has been shown to require TMD8 [74]. This
concept of more hydrophobic regions pulling in less hydrophobic regions
is emerging as a theme in membrane protein insertion and folding [75].
Another study suggested that presenilin forms a ring-like structure [76],
with TMD1 proximal to TMD8. Crosslinking of wild-type cysteines
in PS1 likewise suggested TMD1 and TMD8 proximity [77]. The nine-
transmembrane topology and proximity of TMD1 and TMD8 are also
ﬁndings consistentwith a new crystal structure of a presenilin-like prote-
ase (see later). The apparent topology of SPP and its homologs likewise
determined through insertion of glycosylation sites in loops and at the
C-terminus, also resemble that of presenilins, placing the key aspartates
in the same relative position to each other in themembrane [78]. The ori-
entation of the aspartate-containing transmembrane domains of SPP and
its homologs, however, is opposite that of presenilins (Fig. 2), consistent
with the fact that SPP cleaves signal peptides: presenilins cleave type I
integral membrane proteins, oriented with N-to-C termini going from
SPP
SP
lumen/extracellular
cytosol
si
gn
al
 p
ep
tid
e
SPP
DD
Fig. 2. Membrane topology of signal peptide peptidase (SPP) and its substrates. SPP, like presenilins, has nine transmembrane domains, with TMD 6 and TMD 7 contributing the
active site aspartates. However, the membrane orientation of SPP is opposite that of presenilins. The membrane orientation of SPP substrates is likewise opposite that of presenilin
substrates: the signal peptide of type I integral membrane proteins, released by signal peptidase (SP), runs from cytosol to lumenal/extracellular space going from N- to C-terminus.
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The reported topologies of Aph-1 and Pen-2 [79,80] are as shown in
Fig. 3. Insertion of glycosylation sites in predicted loop regions and near
termini, in combination with selective permeabilization of the plasma
membrane and immunoﬂuorescence microscopy, supported a seven-
TMD topology for Aph-1, with N-terminus in the lumenal/extracellular
space and the C-terminus in the cytosol [81]. The topology of Pen-2 was
deduced using a similar strategy: the N-linked glycosylation sites pres-
ent in the N- and C-terminal domains of Pen-2 were utilized, whereas a
site in the hydrophilic region connecting the two predicted transmem-
brane domains, presumably a loop,was not [80]. This topologywas con-
ﬁrmed using epitope tags near the N- and C-termini. The topology of
Nicastrin, in contrast, has never been seriously in question, as it has
every indication of being a type I integral membrane protein, with a
single transmembrane domain, an N-terminal ectodomain in the extra-
cellular/lumenal space and short C-terminal tail in the cytosol. Consistent
with this notion is the extensive glycosylation of the N-terminal
ectodomain, which is increased upon assembly into the full γ-secretase
complex [82–86]. Tryptic digestion experiments further suggested that
assembly of nicastrin into full complexes leads to a conformationalcytosol
ApNicastrin
Fig. 3. Membrane topology of the other three componchange [87]. Mature, fully glycosylated nicastrin is protected from trypsin
degradation, even as other γ-secretase components are digested.
5. Subunit interactions and stoichiometry
γ-Secretase is so far unique among intramembrane proteases in
being composed of several different proteins: all the others apparently
work alone as single proteins. Coexpression, RNA interference, and the
identiﬁcation of assembly intermediates suggest the order in which
these four subunits come together [61,88,89], and partial dissociation
of the protease complex with detergent offers a model for how these
subunits interact [88]. Assembly of the γ-secretase complex begins in
the endoplasmic reticulum soon after translation and membrane inser-
tion. Nicastrin and Aph-1 assemble into a subcomplex, with nicastrin
remaining in an immature, hypoglycosylated form [90]. Whether
presenilin and Pen-2 interact with each other ﬁrst before assembly
with the nicastrin/Aph-1 subcomplex is unclear, but knockdown of
Pen-2 does lead to a Nicastrin/Aph-1/Presenilin subcomplex in which
presenilin remains as a holoprotein [61,88,91]. Assembly of all four
components results in presenilin autoproteolysis [29,92] into NTF and
CTF subunits, nicastrin maturation through glycosylation, and activelumen/extracellular
h-1 Pen-2
ents of γ-secretase: nicastrin, Aph-1 and Pen-2.
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Partial dissociation of the γ-secretase complex using the nonionic
detergent dodecyl-β-D-maltoside (DDM) followed by 2D PAGE analysis
revealed how the γ-secretase components are arranged in the active
protease complex [94]. As expected, nicastrin interacts with Aph-1,
but PS1 NTF was found to interact with Pen-2 as well as with PS1 CTF,
and nicastrin and Aph-1 together can also interact with PS1 CTF. A
Pen-2/PS1 holoprotein complex was also observed. Other studies have
conﬁrmed the PS1 NTF/Pen-2 interaction and pinpointed transmem-
brane domain 4 of PS1 as the site of contact with Pen-2 [95,96].
Crosslinking studies corroborate these interactions [97]. Bifunctional
chemical crosslinking reagents were used to covalently connect proxi-
mal subunits within endogenous human γ-secretase complexes.
Crosslinked subunits included PS1 NTF and CTF, PS1 NTF and PEN-2,
and NCT and APH-1. PS1 CTF and APH-1 was also observed, providing
further information on the nature of the full, active complex. Site-
directed mutagenesis with co-immunoprecipitation experiments fur-
ther suggested that the C-terminal region of PS1 interacts with the
N-terminal region of the nicastrin TMD [98,99]. Taken together, these
ﬁndings have led to the model for the γ-secretase complex shown in
Fig. 4.
As for the stoichiometry of the γ-secretase complex, this has
been a matter of some controversy, with discrepancies in the
reported size of the complex and in the number of presenilin mol-
ecules per complex. Sizes of 100–150 KDa to 2 MDa have been
reported [35,36,62,83,100,101], and several studies suggested that
two presenilins reside at the catalytic core of the protease complex
[102–104]. However, rigorous biochemical and biophysical experi-
ments have shown that isolated, active complexes contain only one of
each component [105]. Differential epitope tagging of PS1 demonstrat-
ed that one PS1molecule does not co-immunoprecipitate with another.
A similar approach demonstrated the same for Aph-1. Quantitative west-
ern blotting, using epitope-tagged standards of similar size, showed that
Pen-2 and nicastrin were in equimolar amounts to PS1 NTF/CTF withinN
Fig. 4. Model for subunit interaction within the γ-secretase complex and substrate in-
teraction. Presenilin NTF (copper), presenilin CTF (gold), Pen-2 (red), Aph-1 (blue),
and nicastrin (green). Substrate APP CTF (yellow) is shown interacting at the interface
between presenilin NTF and CTF via its transmembrane domain and with nicastrin via
its N-terminus. Substrate then enters the internal active site (pink star) for proteolysis
to Aβ and AICD.active γ-secretase complexes. Consistent with this stoichiometry, the
size of the puriﬁed enzyme was determined to be ~230 kDa by scan-
ning electron microscopy [106]. As both the co-immunoprecipitated
complexes used in the stoichiometry experiments and the puriﬁed
complex used in the sizing experiments were proteolytically active,
able to produce Aβ and AICD from recombinant APP substrate, it
seems clear that one presenilin NTF/CTF heterodimer is sufﬁcient
for functional complexes. However it is not known whether higher-
ordered oligomeric assemblies occur in the context of cellular mem-
branes, and whether such assemblies might have functional differ-
ences from complexes composed of one of each component.
Although SPP does not require other protein cofactors for proteolytic
activity, SPP can form homodimers very rapidly in cells, and these di-
mers are stable enough to allow isolation and analysis [107]. Moreover,
these dimers can be speciﬁcally labeled by a transition-state analog in-
hibitor, suggesting that the dimers are catalytically active. The function-
al importance of these dimers, however, is unclear; dimerization is not
necessary for proteolytic activity, as determined from puriﬁcation of
recombinant SPP from E. coli [72]. Despite the unresolved question of
the existence and relevance of the SPP dimer, the catalytic sites of the
presenilin and SPP appear remarkably similar: their activities are
inhibited by some of the same active site directed peptidomimetics
[108,109] and helical peptides [110], and activity can be modulated by
the same NSAIDs that affect γ-secretase [110].6. Multiple proteolytic functions of γ-secretase
The above mentioned ﬁnding that only one presenilin molecule is re-
quired for γ-secretase activity has mechanistic implications, as it means
that theprotease complex contains only onepair of conserved transmem-
brane aspartates and therefore one active site. This is important, because
the enzyme displays three different types of proteolytic activities: (1) an
autoproteolytic function in which full-length presenilin is cleaved within
the TMD6-TMD7 loop toNTF and CTF to activate the complex for cleaving
other substrates [29,92], (2) an endoproteolytic function of type I integral
membrane protein substrates to release substrate intracellular domains
[15], and (3) a carboxypeptidase function, in which the remaining frag-
ment, containingmost of the transmembrane domain, is trimmed rough-
ly every 3 amino acids until the fragment isﬁnally released [111]. For APP,
initial cleavage at the ε site to release AICD also forms either a 48- or
49-residue Aβ, which contains almost all of the transmembrane domain
[112]. Subsequent processive proteolysis from the C-terminus of these
long Aβ peptides ultimately leads to release of the 38–43-residue secret-
ed forms of Aβ [113]. Similar processive proteolysis of the corresponding
fragment of theNotch receptor apparently also occurs, and this is likely to
be true of other γ-secretase substrates as well [114,115].
Evidence supports two pathways for Aβ production depending on
the exact site of initial ε cleavage: Aβ49→ Aβ46→ Aβ43→ Aβ40 and
Aβ48→ Aβ45→ Aβ42→ Aβ38, ﬁndings particularly supported by
the detection of the corresponding tri- and tetrapeptide products [111].
Alzheimer-causing presenilin mutations can alter the initial site of ε
cleavage to increase formation of Aβ48 over Aβ49 [116], thereby increas-
ing the ratio of secreted Aβ42/Aβ40, which is critical in the aggregation
propensity of the peptide [117]. Recent evidence also shows that the car-
boxypeptidase function of γ-secretase is reduced by such disease-causing
mutations [118,119]. These ﬁndings appear to resolve a long-standing
controversy about how presenilin mutations cause Alzheimer's disease,
with one side suggesting that reduction of γ-secretase proteolytic func-
tion is what ultimately causes synaptic dysfunction and neurodegene-
ration [120] and another camp suggesting that a toxic gain of function,
an increase in Aβ42/Aβ40, is responsible [9]. These ideas may be syn-
thesized by considering that the speciﬁc reduction of the carboxypepti-
dase function by the presenilin mutations results in the increase in the
proportion of longer, more aggregation-prone neurotoxic forms of Aβ
[121–123].
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Inhibitors of γ-secretase and of SPP have served as important
probes for protease structure and function. Transition-state analog in-
hibitors converted to afﬁnity labeling probes tagged both PS1 NTF and
PS1 CTF [38,39], suggesting that the active site lies at the interface be-
tween the two presenilin subunits, consistent with each subunit con-
tributing one of the two conserved aspartates required for proteolytic
function. Transition-state analog inhibitors have also provided evi-
dence for a large S1 pocket [124] and loose sequence speciﬁcity
[27,125,126]. Such probes have been further used to show that the ac-
tive site conformation of γ-secretase is altered by Alzheimer-causing
PS1 mutations [127,128]. Gold-coupling of a transition-state analog
inhibitor has also conﬁrmed the presence of one active site per prote-
ase complex [129].
Interestingly, afﬁnity isolation of the γ-secretase complex using an
immobilized transition-state analog inhibitor revealed co-puriﬁcation
of an endogenous APP substrate, suggesting that substrate can bind to
the enzyme complex even when the active site is occupied by an in-
hibitor [63]. The existence of an initial substrate docking site on
γ-secretase makes sense given the intramembranous nature of the
hydrolytic reaction. The active site, with two aspartates and water,
is predicted to reside in the interior of the complex so as not to
come in thermodynamically unfavorable contact with the hydropho-
bic lipid tails of the membrane. The transmembrane substrate can
move within the bilayer in only two-dimensions and would therefore
be expected to ﬁrst interact on the outer surface of the protease com-
plex before enter in whole or in part into the internal active site.
Designed peptides based on the transmembrane domain of APP
and constrained in a helical conformation can potently inhibit
γ-secretase, apparently by interacting with this docking site [130].
Conversion of these helical peptide inhibitors into afﬁnity labeling re-
agents led to the localization of the substrate docking site to the
presenilin NTF/CTF interface [127]. Transition-state analog inhibitors
also bind directly to the NTF/CTF interface, but at a site clearly distinct
from that of helical peptide inhibitors. These ﬁndings suggest a path-
way for γ-secretase substrate from docking site to active site: upon
binding to the outer surface of presenilin at the NTF/CTF interface,
the substrate can pass, either in whole or in part, between these
two presenilin subunits to access the internal active site (Fig. 4). In-
terestingly, extension of a ten-residue helical peptide inhibitor by
just three additional residues resulted in a potent inhibitor [131]
apparently capable of binding both docking site and active site
[127], suggesting that these two substrate binding sites are relatively
close. Coimmunoprecipation experiments also show that nicastrin
can interact with APP and Notch substrates at their N-termini, consis-
tent with the observation that nicastrin has homology to aminopepti-
dase, but with an essential catalytic residue mutated [132,133]. Thus,
nicastrin may also play a role in substrate recognition (Fig. 4). Anoth-
er report, however, challenges this view [134].
Other compounds have been identiﬁed that havemore subtle effects
on γ-secretase activity. So-called γ-secretase modiﬁers reduce the pro-
duction of aggregation-prone Aβ42 and increase production of shorter,
more soluble forms [135]. Other “Notch-sparing” γ-secretase inhibitors
have been reported to inhibit Aβ production from APP with some de-
gree of selectivity over Notch proteolysis [136–138]. Both types of com-
pounds have the potential to be safer therapeutic agents targeting
γ-secretase than broadly acting inhibitors. While some evidence sup-
ports the interaction of γ-secretase modulators with APP substrate
[139], more compelling evidence favors interaction with the protease
complex [110,140]. Afﬁnity labeling indicates direct interaction of
both modulators and Notch-sparing inhibitors with presenilin NTF
[141–143], although one study found Pen-2 as the target of a novel
class of γ-secretase modulators [144]. The latter study is called into
question, however, by the use of a detergent (Triton X100) that
completely disrupts the protease complex during the afﬁnity labeling.Taken together, these ﬁndings suggest that the γ-secretase complex,
most notably presenilin NTF, contains a pocket that serves as the binding
site of compounds that allosterically regulate the enzyme, rather than
completely blocking access of all substrates. The speciﬁc identiﬁcation
of such allosteric binding sites, especially through co-crystallization,
might allow rational, structure-based design of therapeutic candidates
that target γ-secretase.
8. Cysteine crosslinking studies
Other structural features of the γ-secretase complex, speciﬁcally of
the presenilin component, have been revealed by cysteinemutagenesis
with crosslinking of chemical probes [145,146]. The generation of a
cysteine-less version of presenilin that retains the ability to assemble
with other complex members, to undergo endoproteolysis to NTF and
CTF, and to process APP allowed incorporation of single cysteine resides
at various sites near the key aspartates. Disulﬁde formation with
biotinylated, thiol-containing reagents then provided information
about the relative accessibility of these sites from the aqueous milieu,
allowing the construction of a model in which water can funnel down
to where the aspartates reside (the “catalytic pore” model).
In addition, simultaneous mutation of the two conserved trans-
membrane aspartates to cysteine and apparent intramolecular cross-
linking provided the ﬁrst evidence that these two aspartates are
indeed in close proximity [145], which is required for them to coordi-
nate and serve catalytic function. Using this same approach (cysteine
mutagenesis and crosslinking), two recent studies suggest that TMD
9 serves as a gatekeeper for lateral entry of the substrate TMD
[147,148], as this TMD appears to be ﬂexible, close to the catalytic as-
partate in TMD 6, and a site for inhibitor binding, including a helical
peptide. Still another cysteine-crosslinking study suggests that TMD
1 is in direct contact with TMD 8 [77].
The cysteine mutagenesis/crosslinking approach was further used
to study TMD 1 in detail. The results from these experiments sug-
gested that TMD 1 is located in proximity to the catalytic motif in
TMD 7 as well as to a Pro-Ala-Leu motif between TMD 8 and TMD 9
and directly faces the catalytic pore [149]. Competition experiments
using known γ-secretase inhibitors suggested that the N-terminal re-
gion of TMD 1 functions as a subsite for substrate handling during
proteolysis by γ-secretase. Intriguingly, binding of inhibitors affected
water accessibility of residues at the membrane border of TMD 1,
suggesting the possibility of a dynamic motion of TMD 1 during the
catalytic process. The various conclusions drawn from all the cysteine
mutagenesis/crosslinking studies are mostly supported by a new
structure of an archaeal presenilin homolog (see below).
9. Electron microscopy
Several I-CLiPs that work as single polypeptide chains have now
been crystallized and their structures elucidated at atomic resolution.
This includes a presenilin-like protease (see below). However, a de-
tailed structure of the entire γ-secretase complex is daunting, with its
four different protein components (ﬁve after presenilin autoproteolysis
to NTF and CTF subunits), a size of ~230 kDa, extensive glycosylation of
nicastrin, and a grand total of 19 TMDs. Nevertheless, the puriﬁcation of
the γ-secretase complex [65] has allowed the ﬁrst glimpses into its
structure through electron microscopy (EM). Electron microscopy
with uranyl acetate coating and single particle analysis revealed that
the complex has a globular structure that at low resolution (10–15 Ǻ)
appears rather amorphous [150]. [Another structure, elucidated in
a similar manner but of much poorer resolution (~45 Ǻ), has also
been reported [151]]. Orientation of the complex with respect to
the membrane was established using lectin tagging of the highly
glycosylated nicastrin ectodomain, and the dimensions were measured
as ~75 × 120 × 75 Å. Despite the relatively low resolution, several im-
portant features can be gleaned. The ﬁrst is a rather large low-density
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tive site resides, a characteristic reminiscent of the proteasome. Another
is the presence of two small openings that may be the site of entry for
water. Finally, the complex contains a belt-like density ~60 Ǻ high
that is likely to be the transmembrane region.
More recently, an improved structure of γ-secretase was deter-
mined by cryo-EM at 12 Å resolution [106] (Fig. 5). Cryo-EM reveals a
protein structure itself, rather than a surface of the protein structure
coated by a heavy metal stain. The new cryo-EM structure reveals
three smaller low-density interior regions, which do not coalesce to
form a single chamber as observed in the negative stain structure [150].
The cryo-EM structure has better deﬁnition than the previous negative-
stained structure, in that the ~4 nm thick transmembrane region and
four extracellular density domains are resolved [106], and gave dimen-
sions of ~80 × 90 × 85 Å. The structure also reveals an apparent groove
along the membrane-exposed outer surface that may be the initial
substrate docking site. An 18 Å cryo-EM structure showed similar di-
mensions (100 × 70 × 105 Å) [129]. However, in some respects this
lower-resolution structure appears to bemore compact and has a single
central chamber that interfaces with a concave surface on the extracel-
lular side. This cavity appears to be the site of labeling by a gold-coupled
transition-state analog photoafﬁnity reagent, consistent with this ap-
parently water-accessible cavity containing the active site. This same
study reported the cryoEM structure of the PS1-nicastrin-Aph1 trimeric
complex, which appeared to be quite similar to the full complex,
suggesting that addition of the small (~10 kDa) Pen-2 subunit does
not cause major conformational changes to the complex.
Ultimately, structure elucidation of individual subunits as well as
subcomplexes, by NMR or crystallography (see below) may allow
the piecing together of the entire γ-secretase complex with atomic
level detail, using the lower resolution EM structures as a framework.A
B
lumen/extracellular
cytosol
lumen/extracellular
cytosol
Fig. 5. Structure of the γ-secretase complex at 12 Å resolution as determined by
cryo-electron microscopy. Coloration represents different domains of the complex
and is not meant to imply speciﬁc subunits. However, the large nicastrin ectodomain,
identiﬁed with lectin, is located on the lumenal/extracellular side. The thick red curved
line in panel A identiﬁes a groove on the outside of the membrane-spanning surface
that may be the site of initial substrate binding. The structure reveals three openings,
seen in the cutaway view in panel B, by which catalytic water may gain access to the
active site.Such has been the case for other large and challenging macromolecu-
lar complexes, such as the ribosome.
10. NMR and crystal structures
A fuller understanding of the mechanism of γ-secretase and the na-
ture of substrate recognition and handling requires higher resolution
structural information. As a ﬁrst step toward this goal, the solution struc-
ture of the human presenilin-1 CTF in SDS micelles was determined by
NMR [152]. At ~18 kDa, this protein is just within the current size restric-
tions for protein structure determination by NMR. The human PS1 CTF
was expressed using isotopically labeled amino acids under cell-free
conditions, precipitated, and solubilized in SDS. In addition toNMRexper-
iments to determine local conformation, paramagnetic relaxation en-
hancement was employed on monocysteine mutant versions of the PS1
CTF labeledwithmethanethiosulfonate to determine long-range distance
restraints. Analysis revealed six α-helical regions, with three of these
representing the core of the protein. Only one helical region, correspond-
ing to TMD8 in full-length PS1, showed typical transmembrane character.
TMD7, harboring one of the catalytic aspartates, was a shorter helix, with
the aspartate at the N-terminus and predicted to be within the mem-
brane. TMD 9 was severely kinked, due to the presence of a conserved
proline at residue 455 (full-length PS1 numbering), with the N-terminal
half perpendicular to TMD 7 and TMD 8 and the C-terminal half pointing
toward the surface of the membrane.
Although this structure of the PS1 CTFwas determined in SDS and in
the absence of the other components of the γ-secretase complex, it is in
general agreementwith previous studies. The core structure, with three
α-helical regions representing the predicted TMDs 7, 8 and 9, is consis-
tent with the widely accepted nine-TMD structure of PS1 and with
water-accessibility experiments carried out using cysteine scanning
and labeling.While SDS is considered a denaturing detergent for soluble
proteins, it has been used successfully to determine the NMR solution
structure of other membrane proteins. Nevertheless, differences are to
be expected between this NMR structure and the actual structure of
the PS1 CTF in the context of the full, active γ-secretase complex. In-
deed, some key differences are observed between the NMR structure
and the corresponding region in the crystal structure of a microbial
PSH [153].
Yigong Shi and colleagues worked toward the crystal structure of a
presenilin protease by ﬁrst attempting to express, purify and crystal-
lize eukaryotic PS1 orthologs [153]. When this failed, they turned to
archaeal homologs, as these can display better solution properties
more suitable for crystallization trials. The archaeon Methanoculleus
marisnigri JR1 provided the presenilin homolog (mmPSH) with the
best solution properties. This was fortunate, as mmPSH had already
been identiﬁed as a presenilin homolog, expressed in and puriﬁed
from bacteria, shown to cleave substrate (including one derived
from APP) within the transmembrane domain, and found to be
inhibited by certain γ-secretase inhibitors [154]. However, mmPSH
still required engineering for further optimization for crystallization.
Ultimately, ﬁve mutations were identiﬁed that together provided ex-
cellent properties for crystallization trials. These mutations were
mostly in surface loops and did not affect protease activity, deter-
mined using the membrane protein Gurken as substrate [154]. Crys-
tallization allowed structure determination at 3.3 Å resolution. It
should be mentioned that the crystal structure of another polytopic
aspartyl protease, an archaeal preﬂagellin protease called FlaK, has
also been determined [155]. However, the evolutionary relationship
between FlaK and presenilins is distant at best, the number and corre-
spondence of transmembrane domains between FlaK and presenilins
is different, and the active site aspartates of FlaK are found outside the
membrane. Therefore, FlaK will not be further discussed here.
The mmPSH structure revealed nine transmembrane domains,
consistent with the most accepted experimental ﬁndings, and the
conserved aspartates in TMD 6 and TMD 7 (Asp162 and Asp220,
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The N-terminal region with TMDs 1–6 forms a horseshoe-shaped
structure which partially surrounds TMDs 7–9. Although the trans-
membrane aspartates are proximal, they are not close enough or ori-
ented quite properly to work together to activate water for catalysis.
Shi and colleagues speculate that interaction with substrate may lead
to proper formation of the active site. However, it is also possible that
the misalignment and slight spacing between the aspartates is an ar-
tifact of crystal packing. Indeed, mmPSH crystallized as a tetramer,
and the biological relevance of this assembly is unclear. The two as-
partates are at the bottom of a cavity exposed to the aqueous environ-
ment (corresponding to the cytosol in human presenilin), providing a
reasonable explanation for how catalytic water accesses the intra-
membrane active site.
Another interesting and unexpected feature of the structure is the
presence of a hole that runs the length of the transmembrane region,
surrounded by TMDs 2, 3, 5 and 7 (Fig. 6). This hole is mostly hydro-
phobic and may be plugged up by a lipid molecule in the context of
the membrane. Although the hole is large enough to accommodate
small ions, and some evidence suggests that presenilin has properties
of a calcium channel [156], this pore is highly hydrophobic and is un-
likely to allow ions to traverse it. This hole, like the tetrameric ar-
rangement, may be an artifact of crystal packing. Alternatively, this
particular structure of mmPSH may represent one among a continu-
um of possible conformations, with the hole forming during the pro-
cess of substrate interaction. Shi and colleague hypothesize that
substrate entry likely occurs between TMD 6 and TMD 9, which is
consistent with cysteine scanning and crosslinking suggesting that
TMD 9 may act as a substrate gate [147,148]. On the other hand, the
accessibility of the active site from this trajectory seems quite hin-
dered (Fig. 6). In contrast, the active site seems much more accessible
between TMD 2 and TMD 6, where there is a relatively large gap. In-
terestingly, a TMD of another mmPSH molecule is packed into this
gap. Thus, this transmembrane helix of the neighboring mmPSH mol-
ecule may occupy the initial substrate docking site, and this docking
may lead to the creation of the hole by conformational adjustment
of TMD 2 (and TMD 3 along with it). Together, TMD 2 and TMD 3
may act as a hinge, swinging open to accommodate substrate binding.
Such ideas, while speculative, are now very testable with the new
structure.6
7
9
8
1
5
4
3
2
hole
Substrate
entry?
Substrate
entry?
Fig. 6. Crystal structure of the archaeal presenilin homolog mmPSH. Cartoon represen-
tation, viewed looking perpendicular to the membrane, allows visualization of the ar-
rangement of the nine transmembrane domains. The side chains of the conserved
aspartates in TMD 6 and TMD 7, forming the active site, are shown as sticks. A hole
that traverses the entire membrane is formed by TMDs 2, 3, 5 and 7. Two potential
routes of substrate access to the active site are also denoted. Rendered from RCSB
PDB 4HYG.The sequences of mmPSH and human PS1 are 19.3% identical and
52.8% similar, and signature sequences, including the aspartate-
containing regions in TMD 6 and TMD7 are highly conserved. Thus,
the structures of mmPSH and human PS1 likely share the same basic
fold. Interestingly, mapping sites of Alzheimer-causing mutations in
human PS1 onto the mmPSH structure reveals key regions where
thesemutations tend to be located. One is the active site cavity: residues
in TMDs 1, 5, 6, 7, 8 and 9 contributing to the active site are mutated in
familial Alzheimer's disease in the corresponding residues of human
PS1 (Fig. 7A). Another major site of Alzheimer mutations is the hydro-
phobic hole that traverses the membrane (Fig. 7B). TMDs 2, 3, 5 and 7
all contribute residues to this hole that are also sites of familial
Alzheimer mutations. Many of the mutations, particularly in TMDs 2
and 5, are found speciﬁcally along the side of the helix of the TMD facing
into this pore. A third major site of mutations is in TMD 1, again along
one side of the helical TMD, but in this case the residues face outward
toward themembrane (Fig. 7C). In human presenilins, these TMD 1 res-
iduesmay interact with one of the other components of the γ-secretase
complex, and mutations may alter activity by affecting the subunit
interface.
The above discussion on Alzheimer PS1 mutations is offered as
speculation and as one way to consider the mmPSH structure for for-
mulating speciﬁc testable hypotheses. However, caution should be
exercised in extrapolating from the mmPSH structure to PS1 struc-
ture–function relationships in the context of the full γ-secretase com-
plex. First, mmPSH does not require other subunits for proteolytic
activity, although a recent report demonstrates that under the right
conditions, a human PS1 can have catalytic activity without its part-
ner proteins [157]. Second, as pointed out earlier, γ-secretase displays
three different proteolytic functions: an autoproteolytic function, an
endoproteolytic function and a carboxypeptidase function, and it is
this last function that is apparently altered by Alzheimer-causing
presenilin mutations [118,119]. Whether mmPSH displays this car-
boxypeptidase function is unknown. If so, then it would be worth-
while to test the effects of human Alzheimer mutations in mmPSH
on the trimming function versus the endoproteolytic function.
11. Conclusions and perspective
Since the initial discovery of presenilin as the catalytic component of
γ-secretase in 1999, much has been learned about the structure of this
novel intramembrane aspartyl protease and its interaction with cofac-
tor proteins and substrates. In particular, a nine-TMD structure has
been conﬁrmed, with the transmembrane aspartates located in close
proximity. Subcomplex formation, crosslinking and partial detergent
dissociation have offered a model for subunit interactions. Cysteine
scanning with crosslinking has provided information about proximity
of speciﬁc residues and TMDs, water accessibility and inhibitor binding
sites. Electronmicroscopy has revealed the ﬁrst glimpses of the full pro-
tease complex, and NMR has provided a solution structure for the PS1
CTF. Most notable is the new crystal structure of a microbial presenilin
homolog, which reveals for the ﬁrst time the basic fold of this family
of I-CLiPs and provides a platform for generating speciﬁc hypotheses re-
garding structure–function relationships.
Moving forward, it will be worthwhile to determine the structures
of other presenilin homologs, including the SPP family. Determining
the structure of a human presenilin, ideally in the context of the full
γ-secretase complex, would also be highly worthwhile. This may be
accomplished by crystallization of the entire complex, or more likely,
by crystallizing individual components and subcomplexes and using
the EM structures as the framework to piece together this 3D jigsaw
puzzle. It will also be important to determine the nature of substrate
interaction and how substrate accesses the active site. Finally, deter-
mination of inhibitor–protease complexes would allow rational drug
design toward identifying potent and selective compounds that safely
lower Aβ production by γ-secretase without unduly interfering with
CBA
Fig. 7. Mapping of sites of Alzheimer-causing presenilin mutations onto the space-ﬁlled structure of mmPSH. Corresponding sites in mmPSH are colored according to transmem-
brane domain: TMD 1 (dark red), TMD 2 (orange), TMD 3 (pink), TMD 4 (brick red), TMD 5 (magenta), TMD 6 (light brown), TMD 7 (dark brown), TMD 8 (olive), and TMD 9 (pale
yellow). (A) The active site is lined with sites of mutation. The catalytic aspartates are colored according to atom (carbon: green, oxygen: red). (B) The membrane hole is likewise
lined with sites of mutations. (C) Sites of mutations in TMD 1 run the length of one side of the helix facing the membrane and may together correspond to a site of protein–protein
interaction in the γ-secretase complex. Rendered from RCSB PDB 4HYG.
2894 M.S. Wolfe / Biochimica et Biophysica Acta 1828 (2013) 2886–2897cleavage of critical substrates such as the Notch receptor. The hope is
that these future milestones in the study of presenilin and the
γ-secretase complex are years away, rather than decades.Acknowledgements
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